17-ODYA

17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC₅₀<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes^[1][2][3]. 17-ODYA is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. In Vivo: Infusion of 17-ODYA (16.5 nmol/min) directly into the renal cortical interstitium of rats produced a diuresis and a natriuresis which were associated with an increase in renal papillary blood flow in the absence of changes in renal blood flow, cortical blood flow or glomerular filtration rate^[2].
17-ODYA (0.28 mg/kg; intracoronary; infusion for 2 to 3 minutes; dogs) markedly inhibits 20-HETE production during ischemia-reperfusion and produces a profound reduction in myocardial infarct size^[3].